Efinaconazole in the Treatment of Onychomycosis

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2015 Jun 18

PMID 26082652

Citations 11

Authors

Shari R Lipner

Richard K Scher

Affiliations

Soon will be listed here.

Abstract

Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis.

Citing Articles

Impact of new antifungal medications on onychomycosis prescriptions and costs in Japan: A nationwide claims database study.

Miyachi H, Sato D, Sakamaki K, Togawa Y, Yoshimura K J Dermatol. 2024; 51(9):1172-1179.

PMID: 39115330 PMC: 11483898. DOI: 10.1111/1346-8138.17393.

Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.

Axler E, Lipner S Infect Drug Resist. 2024; 17:819-843.

PMID: 38463386 PMC: 10922011. DOI: 10.2147/IDR.S431526.

Formulation-by-Design of Efinaconazole Spanlastic Nanovesicles for Transungual Delivery Using Statistical Risk Management and Multivariate Analytical Techniques.

Almuqbil R, Sreeharsha N, Nair A Pharmaceutics. 2022; 14(7).

PMID: 35890316 PMC: 9324635. DOI: 10.3390/pharmaceutics14071419.

ONYCHOMYCOSIS: A Review of New and Emerging Topical and Device-based Treatments.

Kawa N, Lee K, Anderson R, Garibyan L J Clin Aesthet Dermatol. 2020; 12(10):29-34.

PMID: 32038746 PMC: 6937150.

Preparation and evaluation of a highly skin- and nail-permeable efinaconazole topical formulation for enhanced treatment of onychomycosis.

Lee B, Pangeni R, Na J, Koo K, Park J Drug Deliv. 2019; 26(1):1167-1177.

PMID: 31738083 PMC: 6882438. DOI: 10.1080/10717544.2019.1687612.

References

Zeichner J, Gold L, Korotzer A . Penetration of ((14)C)-Efinaconazole Topical Solution, 10%, Does Not Appear to be Influenced by Nail Polish. J Clin Aesthet Dermatol. 2014; 7(9):34-6. PMC: 4174918. View

Kircik L . Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach. J Drugs Dermatol. 2015; 13(12):1457-61. View

Robbins J . Treatment of onychomycosis in the diabetic patient population. J Diabetes Complications. 2003; 17(2):98-104. DOI: 10.1016/s1056-8727(02)00199-x. View

Ghannoum M, Hajjeh R, Scher R, Konnikov N, Gupta A, Summerbell R . A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000; 43(4):641-8. DOI: 10.1067/mjd.2000.107754. View

Jo W, Glynn M, Nejishima H, Sanada H, Minowa K, Calvarese B . Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment. Regul Toxicol Pharmacol. 2014; 70(1):242-53. DOI: 10.1016/j.yrtph.2014.07.012. View

Rich P . Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early. J Drugs Dermatol. 2015; 14(1):58-62. View

Tatsumi Y, Nagashima M, Shibanushi T, Iwata A, Kangawa Y, Inui F . Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013; 57(5):2405-9. PMC: 3632939. DOI: 10.1128/AAC.02063-12. View

EVANS E, Sigurgeirsson B . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ. 1999; 318(7190):1031-5. PMC: 27831. DOI: 10.1136/bmj.318.7190.1031. View

Tatsum Y, Yokoo M, Arika T, Yamaguchi H . KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. Microbiol Immunol. 2002; 46(7):425-32. DOI: 10.1111/j.1348-0421.2002.tb02716.x. View

10.

Scher R, Breneman D, Rich P, Savin R, Feingold D, Konnikov N . Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998; 38(6 Pt 2):S77-86. DOI: 10.1016/s0190-9622(98)70490-6. View

11.

Tosti A, Elewski B . Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life. J Clin Aesthet Dermatol. 2014; 7(11):25-30. PMC: 4255695. View

12.

Lee R, Liu T, Barker K, Lee R, Rogers P . Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans. J Antimicrob Chemother. 2005; 55(5):655-62. DOI: 10.1093/jac/dki105. View

13.

Schein J, Gause D, Stier D, Lubeck D, Bates M, Fisk R . Onychomycosis. Baseline results of an observational study. J Am Podiatr Med Assoc. 1997; 87(11):512-9. DOI: 10.7547/87507315-87-11-512. View

14.

Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M, Faergemann J . A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix.... Br J Dermatol. 2007; 157(1):149-57. DOI: 10.1111/j.1365-2133.2007.07974.x. View

15.

Rodriguez R, Low C, Bottema C, Parks L . Multiple functions for sterols in Saccharomyces cerevisiae. Biochim Biophys Acta. 1985; 837(3):336-43. DOI: 10.1016/0005-2760(85)90057-8. View

16.

Elewski B, Pollak R, Pillai R, Olin J . Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space. J Drugs Dermatol. 2015; 13(11):1394-8. View

17.

Chacon A, Franca K, Fernandez A, Nouri K . Psychosocial impact of onychomycosis: a review. Int J Dermatol. 2013; 52(11):1300-7. DOI: 10.1111/ijd.12122. View

18.

Markinson B, Caldwell B . Efinaconazole Topical Solution, 10%: Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis. J Am Podiatr Med Assoc. 2015; . DOI: 10.7547/14-088.1. View

19.

Siu W, Tatsumi Y, Senda H, Pillai R, Nakamura T, Sone D . Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013; 57(4):1610-6. PMC: 3623347. DOI: 10.1128/AAC.02056-12. View

20.

Diao Y, Zhao R, Deng X, Leng W, Peng J, Jin Q . Transcriptional profiles of Trichophyton rubrum in response to itraconazole. Med Mycol. 2008; 47(3):237-47. DOI: 10.1080/13693780802227308. View